Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $2.4700 (-5%) ($2.4500 - $2.6500) on Fri. Apr. 22, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.21% (three month average) | RSI | 31 | Latest Price | $2.4700(-5%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -2.2% a day on average for past five trading days. | Weekly Trend | HTBX declines -4.6% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) OIH(78%) SPY(74%) XOP(72%) INDA(71%) XLI(67%) | Factors Impacting HTBX price | HTBX will decline at least -2.605% in a week (0% probabilities). ACES(-36%) IGOV(-15%) ARKG(-14%) ICLN(-10%) TAN(-8%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.605% (StdDev 5.21%) | Hourly BBV | -0.9 () | Intraday Trend | -3.9% | | | |
|
1 - 5 Day Possible Target | $-9.23(-473.68%) | Resistance Level | $2.88 | 5 Day Moving Average | $2.73(-9.52%) | 10 Day Moving Average | $2.75(-10.18%) | 20 Day Moving Average | $2.88(-14.24%) | To recent high | -21.6% | To recent low | 17.6% | Market Cap | $272m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |